Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Bumble Inc (BMBL) vs Citius Pharmaceuticals Inc (CTXR) Price & Performance

Bumble IncTrade
Citius Pharmaceuticals IncTrade

Price performance (Past 24H)

Key statistics

Bumble Inc vs Citius Pharmaceuticals Inc — how do they compare? Bumble Inc trades at $2.62 (market cap $366.87M), while Citius Pharmaceuticals Inc trades at $0.77 (market cap $20.01M). The key difference: Bumble Inc is far larger — about 18.3× Citius Pharmaceuticals Inc's market cap, and Citius Pharmaceuticals Inc is trading nearer its 52-week high, Bumble Inc nearer its low. Which is the better fit depends on your goals.

BMBLCTXR
Market Cap
$366.87M$20.01M
Sector
TechnologyHealth
52-Week High
$7.17$1.82
52-Week Low
$2.70$0.48
Enterprise Value
$672.73M$16.23M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Bumble Inc

Bumble (BMBL) trades at $2.59, down 5.13% with bearish technical signals and negative earnings momentum after Q2 2026 missed expectations. The company faces declining revenue and persistent net losses despite a high gross margin of 72.84%. Recent strategic shifts include removing the women-first messaging rule and exploring a potential sale to revive growth amid user engagement challenges.

The outlook remains cautious with significant execution risks from product overhauls and competitive pressures. While valuation ratios like P/S (0.38) and P/B (0.71) appear attractive, profitability concerns and negative cash flow trends offset potential upside. Analyst consensus is mixed with a $3.62 price target but 74% hold ratings reflecting uncertainty.

Citius Pharmaceuticals Inc

CTXR trades at $0.7554, up 11.58% today, with a bullish technical signal from moving averages. The company reported a net loss of $37.43M for 2025, with a negative net income margin of -823.34%, but shows revenue growth from its LYMPHIR launch. Recent news highlights commercial expansion and positive clinical data presentations at ASCO 2026.

The outlook is speculative; analyst consensus is strongly bullish (83.3% Buy), but high cash burn and consistent earnings misses pose significant risks. Investment potential hinges on successful commercialization of LYMPHIR to achieve profitability.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Bumble Inc

Bumble Inc is engaged in offering online dating services. The company operates two apps, Bumble and Badoo, where users come on a monthly basis to discover new people and connect with each other.

Read more on BMBL

About Citius Pharmaceuticals Inc

Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.

Read more on CTXR